J40-J47 – Chronische Krankheiten der unteren Atemwege: G-BA benefit assessments

19Decisions

38Patient groups

Added benefit by patient group

Considerable2
Minor8
Not proven27
Lesser benefit1

Diseases in this disease block

J44 Sonstige chronische obstruktive Lungenkrankheit 10 decisions
J45 Asthma bronchiale 9 decisions

Decisions, newest first

Each decision lists only the patient groups coded with a disease in this disease block.

2026-10-01ExdensurDepemokimabNot proven: 2 of 2 patient groups
2026-09-03NucalaMepolizumabNot proven
2025-02-06DupixentDupilumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
2023-05-12TezspireTezepelumabNot proven: 2 of 2 patient groups
2022-10-06DupixentDupilumabNot proven
2021-02-04Enerzair BreezhalerIndacaterol/Glycopyrronium/MometasonNot proven
2020-02-20DupixentDupilumabNot proven: 2 of 2 patient groups
2019-05-02Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
2019-03-22NucalaMepolizumabNot proven
2018-08-16Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
2018-08-02FasenraBenralizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
2017-07-06CinqaeroReslizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
2016-07-21NucalaMepolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
2016-07-21Incruse Ellipta (previously Incruse)UmeclidiniumNot proven: 2 of 2 patient groups
2016-04-07Bretaris GenuairAclidiniumbromidConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
2016-02-04Spiolto Respimat Olodaterol/TiotropiumMinor: 1 of 2 patient groupsLesser benefit: 1 of 2 patient groups
2015-07-16Brimica GenuairFormoterol/AclidiniumbromidConsiderable: 1 of 4 patient groupsMinor: 1 of 4 patient groupsNot proven: 2 of 4 patient groups
2015-01-08Anoro ElliptaUmeclidinium/VilanterolNot proven: 2 of 2 patient groups
2014-05-08Ultibro BreezhalerIndacaterol/GlycopyrroniumMinor: 2 of 4 patient groupsNot proven: 2 of 4 patient groups

Data status: 2026-10-29